: iStockAnalyst.com Symbols Feed

ImmunoCellular (OTC: IMUC.OB) Notches Deal For New Cancer Stem Cell Vaccine Target

Wed, 02 Dec 2009 15:04:42 GMT

In an option agreement announced today with MD Anderson Medical Center, ImmunoCellular Therapeutics (OTC: IMUC.OB) has acquired the rights to novel peptides that elicit a T-cell immune response against validated cancer stem cell targets known as the Notch and Numb pathways.[More...]

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

BioMed News Bytes: Merck KGaA, BioMarin, Cytori, Theravance

Mon, 30 Nov 2009 21:55:06 GMT

On 11/27/09, Theravance (NASDAQ: THRX) announced that it received a Complete Response Letter (CRL) from the FDA for the telavancin New Drug Application (NDA) for the treatment of nosocomial pneumonia (NP). VIBATIV (telavancin) is approved in the US/Canada for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria.[More...]

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Sat, 28 Nov 2009 15:59:46 GMT

Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease. Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular[More...]

US Equity Movers and Shakers, Mid-Session, 11th November

Wed, 11 Nov 2009 17:47:40 GMT

S&P 500 - Risers Pulte Homes Inc. (PHM) $10.04 +6.13% Lennar Corp. Class A (LEN) $15.17 +6.08% KB Home (KBH) $15.56 +5.99% D R Horton Inc. (DHI) $12.30 +5.18% M B I A Inc. (MBI) $3.69 +4.83% Marshall & Ilsley (MI) $5.48 +4.77% N Y Times Class A (NYT) $9.07 +4.61% Sun Microsystems Inc. (JAVA) $8.49 +4.17% Nvidia Corp. (NVDA) $13.66 +4.04% Developers Diversified Reality (DDR) $8.84 +3.88% S&P 500 - Fallers Macy's Inc. (M) $17.83 -8.23% Adobe Systems Inc. (ADBE) $34.63 -5.38% Gamestop Corp. (GME) $24.14 -4.13% American International Group Inc. (AIG) $36.24 -3.59% Owens-Illinois Inc. (OI) $33.90 -2.45% Southwestern Energy (SWN) $44.42 -2.40% Motorola Inc. (MOT) $8.64[More...]

Wall Street Ends Mostly Lower, Boeing (NYSE: BA) Tumbles

Tue, 10 Nov 2009 22:16:44 GMT

US stocks finished mixed on Tuesday as investors took a breather after Monday's sharp rally which pushed the Dow Jones industrial average to its highest level this year.[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

Is Bad News Good Again?

Mon, 09 Nov 2009 13:29:08 GMT

There are times in the market when the action make little sense. For example, most investors probably expected the market to decline when the Labor Dept. reported that the Unemployment Rate hit the highest level since 1983. However, we just might be ent[More...]

Wall Street Closes Higher, General Electric (NYSE: GE) Rallies

Fri, 06 Nov 2009 23:14:45 GMT

US stocks finished higher on Friday as investors shrugged off disappointing government data showing the unemployment rate hit 10.2 percent in October - the highest in 26-1/2 years.[More...]

Wall Street Ends Volatile Session Mixed, Merck (NYSE: MRK) Soars

Wed, 04 Nov 2009 22:15:28 GMT

US stocks finished mostly higher on Wednesday after Federal Reserve left benchmark interest rate unchanged at near zero and said that it will keep them low for an extended period.[More...]

Business Highlights

Mon, 30 Nov 2009 21:46:00 GMT

Worries that Dubai washing its hands of debt woes
DUBAI, United Arab Emirates (AP) - If global investors were looking for reassurances from Dubai that it would stand behind its massive, debt-swamped investment conglomerate, they got none Monday.
Many investors are hoping that Dubai World will either openly discuss restructuring of some $60 billion in debt with its creditors, or that Dubai's larger, oil-rich neighbor, Abu Dhabi, will step in to restore confidence by promising to foot any bills.

: iStockAnalyst.com Symbols Feed

ImmunoCellular (OTC: IMUC.OB) Notches Deal For New Cancer Stem Cell Vaccine Target

Invest In HealthCare!

BioMed News Bytes: Merck KGaA, BioMarin, Cytori, Theravance

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

US Equity Movers and Shakers, Mid-Session, 11th November

Wall Street Ends Mostly Lower, Boeing (NYSE: BA) Tumbles

Big Pharma And Biotech - Industry Outlook

Is Bad News Good Again?

Wall Street Closes Higher, General Electric (NYSE: GE) Rallies

Wall Street Ends Volatile Session Mixed, Merck (NYSE: MRK) Soars

Business Highlights

Merck denies knowing risk of Vioxx

New Jersey index reaches a yearly high

Study: Niacin, statins better than Zetia

Drug industry raises prices by 9 percent

Business Highlights

Feds side with investors in Vioxx suit

Schering-Plough Shares Hit Premerger Bump -- Fails Expectations, but Merck Deal Encouraging

Schering-Plough Shares Hit Premerger Bump

Bristol-Myers posts higher 3Q sales, lower profit

Market Watch: Sunwin International Neutraceuticals - November 10, 2009

Merck and Schering-Plough to Complete Merger Today

Corporate Office Properties Trust Reports Third Quarter 2009 Results

Ev3 Reports 2009 Third Quarter Financial Results

Merck Announces Third-Quarter 2009 Financial Results

Global Health Ventures Inc. (OTCBB: GHLV) Commences an Investment Road Show, Starting in Montreal, Quebec and Then Presenting in London, England

UBS Investment Bank Strengthens Healthcare Banking Team By Hiring Four Managing Directors

Stock in Focus: Sunwin International Neutraceuticals -- September 16, 2009

GTx Inc. (GTXI) Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell

Merck Wins SINGULAIR® Patent Infringement Lawsuit

Form 4 Merck & Co. Inc. For: Nov 19 Filed by: KOHAN RAUL E (10K)

Form 4 Merck & Co. Inc. For: Nov 19 Filed by: BARSHAY STANLEY F (10K)

Form 4 Merck & Co. Inc. For: Nov 19 Filed by: Bowles Richard S III (10K)

Form 4 Merck & Co. Inc. For: Nov 03 Filed by: LAZARUS ROCHELLE B (10K)

Form 4 KOHAN RAUL E For: Nov 03 (10K)

Form 4 Turner Mervyn For: Nov 03 (10K)

Form 4 Bowles Richard S III For: Nov 03 (10K)

Form 4 BARSHAY STANLEY F For: Nov 03 (10K)

Form 4 KIDDER C ROBERT For: Nov 03 (10K)

Form 4 RUSSO PATRICIA F For: Nov 03 (10K)